BASKING RIDGE, N.J., March 28, 2011 /PRNewswire/ — Regado
Biosciences, Inc., a privately held company pioneering the
development of antithrombotic aptamers with active control agents,
announced that Thomas J. Povsic, MD, PhD, Assistant Professor of
Medicine at Duke University, will present results of the RADAR
Phase 2b clinical trial for the Company’s lead product, the REG1
anticoagulation system, at the i2 Summit during the American
College of Cardiology 2011 60th Annual Scientific Session &
Expo.
The presentation, “A Randomized,
Partially-Blinded, Multi-Center, Active-Controlled,
Dose-ranging Study Assessing the
Safety, Efficacy and Pharmacodynamics of the REG1
Anticoagulation System Compared to Unfractionated Heparin or Low
Molecular Weight Heparin in Subjects with Acute Coronary Syndromes:
Primary Results of the RADAR Randomized Clinical Trial,” will be
given during an i2 Special Session entitled: “Interventional
Featured Clinical Studies I” on Sunday, April 3, 2011 at 1:15 p.m.
CDT at the Ernest N. Morial Convention Center in New Orleans,
LA.
REG1 comprises a two-component system; a highly selective Factor
IXa inhibiting aptamer, pegnivacogin, and its complementary
specific active control agent, anivamersen. Anivamersen can
be used to selectively reverse (completely or partially) the
anticoagulant effect of pegnivacogin in real time.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a private biopharmaceutical company
pioneering a new therapeutic technology with the creation and
development of proprietary controllable aptamer drug systems.
Each system comprises a nuclease-stabilized RNA aptamer, the
therapeutic effect of which can be reversed partially or completely
in real time by its specific and complementary oligonucleotide
active control agent. This technology is being applied to
injectable antithrombotics (including antico
‘/>”/>
